01 Pharmaceutical-Grade Formulation Becoming More Technically Sophisticated Formulation challenges such as low water solubility and variable oral absorption are shaping pharmaceutical CBD development around more controlled delivery systems. Researchers are applying Quality by Design methods, optimized excipients, and solid-dose formats to improve consistency; a 2026 study developed CBD orally disintegrating tablets containing 10 mg per tablet with disintegration times of about 13–15 seconds. This work supports a shift toward standardized pharmaceutical formulations with tighter control over dosage, stability, and product performance.
02 Regulatory Frameworks Moving Toward More Defined Oversight Differences between drug, food, and supplement rules continue to shape how CBD products are classified and developed across regulated markets. U.S. regulators have stated that existing food and dietary-supplement pathways are not appropriate for CBD and have called for a separate framework that could address labeling, contaminant controls, content limits, and other safeguards. Clearer oversight would give manufacturers more defined requirements for product development, quality control, and compliant market participation.
September 2025 CV Sciences expanded its PlusCBD™ product portfolio with new hemp-derived CBD formulations focused on wellness applications, strengthening its position in the cannabinoid consumer products segment.
July 2025 Canopy Growth expanded its CBD and wellness product portfolio by advancing cannabinoid-based consumer products and strengthening brand initiatives across regulated markets.
June 2025 Tilray Brands expanded its cannabinoid wellness portfolio by advancing hemp-derived CBD product offerings and strengthening its presence in consumer wellness markets through product development initiatives.
May 2025 Charlotte’s Web expanded its cannabidiol (CBD) product portfolio by introducing new hemp-derived wellness products and strengthening distribution initiatives across retail and online channels.